Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

Background: Up to 60% of metastatic breast cancer (mBC) cases historically classified as human epidermal growth factor receptor 2 (HER2)-negative may be HER2-low, expanding options towards new HER2 targeted treatments. Greater understanding of the current therapeutic journey of this population can h...

Descripción completa

Detalles Bibliográficos

Autores principales:	Shanu Modi, Danalyn Byng, Suyuan Zhang, Yan Xiong, Shannon Hunter, Kyle Dunton, Tara Harding, William Jacot
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2026-04-01
Colección:	Breast
Materias:	Metastatic breast cancer Real-world evidence HER2-Low HR+ Trastuzumab deruxtecan
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S0960977626000317
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!